![TG Therapeutics, Inc. logo](/logos/TGTX.webp)
TG Therapeutics, Inc.
NASDAQ:TGTX
Overview | Financials
Company Name | TG Therapeutics, Inc. |
Symbol | TGTX |
Currency | USD |
Price | 22.03 |
Market Cap | 3,410,750,690 |
Dividend Yield | 0% |
52-week-range | 6.46 - 25.7 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Michael S. Weiss Esq. |
Website | https://www.tgtherapeutics.com |
An error occurred while fetching data.
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD